Hantaan/Puumala Information Form |
The purpose of this randomized trial is to evaluate the safety and reactogenicity of the Hantaan virus vaccine candidate, the Puumala virus vaccine candidate, and the combination of the two vaccines. These two vaccines do not contain live virus and are not able to produce live virus. Both vaccines and the combination vaccine will be administered using an electroporation device (a device that sends electrical pulses to improve the uptake of DNA into the cells), that will either introduce the vaccine intradermally or intramuscularly.
We are asking you for 11 visits over 8 months, and three of these visits are for vaccination. The vaccination visits are scheduled for day 1, day 28, and day 56. The compensation is about $1560 for participating in the study.